SENS - Senseonics announces U.S. launch of new glucose monitoring system

MedTech firm, Senseonics (NYSE:SENS) joined its partner Ascensia Diabetes Care to announce on Wednesday that the first commercial patient has been implanted with Eversense E3, the company’s next-generation continuous glucose monitoring system. The U.S. launch of Eversense E3 comes weeks after the U.S. Food and Drug Administration (FDA) approved the product early this year. “Today marks a major milestone in the history of diabetes care, advancing our Eversense CGM offering so that patients with diabetes can live more freely,” Senseonics (SENS) Chief Executive Tim Goodnow remarked. According to the company, with a 6-month sensor wear duration, Eversense E3 is the longest-lasting CGM device available for use in the U.S. Read: announcing the FDA approval in February, Senseonics (SENS) projected $14M – $18M in global net revenue for this year.

For further details see:

Senseonics announces U.S. launch of new glucose monitoring system